Clinical trials
Phase 1 Thalassemia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 3 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Terminated | 3 |
| Unknown status | 3 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 4 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| Hangzhou Zede Pharma-Tech Co., Ltd. | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| Allife Medical Science and Technology Co., Ltd. | 1 |
| Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 1 |
| Bellicum Pharmaceuticals | 1 |
| Catherine Bollard | 1 |
| City of Hope Medical Center | 1 |
| Duke University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thalassemia | 23 |
| Anemia, Sickle Cell | 8 |
| Hemoglobinopathies | 6 |
| Iron Overload | 3 |
| Anemia | 2 |
| Anemia, Diamond-Blackfan | 2 |
| Severe Combined Immunodeficiency | 2 |
| beta-Thalassemia | 2 |
| Anemia, Hemolytic | 1 |
| Anemia, Hemolytic, Congenital | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.